Peregrine plunges on bad bavituximab data

21:20 EDT 27 Jun 2013 | SCRIP

Tustin, California-based Peregrine buried its latest bad clinical trial news in the middle of a press release regarding the Phase III trial design for bavituximab plus docetaxel in the second-line treatment of non-small cell lung cancer (NSCLC). The....

Original Article: Peregrine plunges on bad bavituximab data

NEXT ARTICLE

More From BioPortfolio on "Peregrine plunges on bad bavituximab data"

Search BioPortfolio:
Loading
Advertisement

Relevant Topics

Prostate Cancer
Latest News Clinical Trials Research Drugs Reports Corporate
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

Gilotrif (afatinib)
Latest News Clinical Trials Research Drugs Reports Corporate
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...

Advertisement

Searches Linking to this Story